Ann Clin Med Res | Volume 2, Issue 5 | Review Article | Open Access
Amol Amonkar*, Frazer CS Rodrigues, Bhagyashree Sukhthanker and Jude Rodrigues
Department of Surgery, Goa Medical College, India
*Correspondance to: Amol Amonkar
Fulltext PDFSARS-CoV-2 has been postulated as the causative organism for coronavirus disease 2019 and thereby also leading to Severe Acute Respiratory Distress Syndrome and a serious health threat to humanity. The high number of COVID-19 cases around the world is overwhelming hospitals thereby pushing global death toll to over 3706,752 which coerced clinicians, epidemiologists and health experts from around the world in a desperate need to find newer treatment options like corticosteroids. Severe coronavirus disease is currently managed by systemic glucocorticoids. In the Pretext of COVID-19 disease being managed by systemic glucocorticoids, COVID 19 associated pulmonary aspergillosis is increasingly recognized as a complication, mucormycosis is coming forward as a problem. In this paper, we are reviewing the existing literature on CAM (Coronavirus Associated Mucormycosis) with regard to its pathogenesis, clinical features and treatment options. Mucormycosis (CAM) is an extremely rare clinical entity and only handfuls of cases are reported till date. This particular paper will throw light on COVID-19 Associated Mucormycosis, its implications on steroid use and also its therapeutic options in detail so as to understand this clinical entity and its social and health implications it has on the society.
Covid-19; Covid; Corona Virus; Coronavirus disease 2019; SARS-CoV-2; Coronavirus; Mucormycosis; Steroids; Pandemic; Mucorales
Amonkar A, Rodrigues FCS, Sukhthanker B, Rodrigues J. Coronavirus Disease Associated Mucormycosis (CAM) - A Novel Threat: A Review of Literature. Ann Clin Med Res. 2021; 2(5): 1042..